New CEO for UniQuest

The University of Queensland (UQ) commercialisation company UniQuest has announced the appointment of its new CEO, Dr Dean Moss. The company specialises in worldwide technology transfer.

UniQuest Chairman Dr Carrie Hillyard said an “international hunt” was undertaken for the new CEO by a global search consultancy firm.

“After an exhaustive selection process, Dr Moss was chosen for his experience across science, universities, business, management and commercialisation in Australia, the USA and the UK,” said Dr Hillyard.

Dr Moss, who has a PhD in Medicine from UQ, joined UniQuest’s Technology Commercialisation division in 2005 as the General Manager responsible for leadership, business development and management of the company’s life sciences activities. He has been acting CEO since February 2013.

He has been a managing director or a senior manager in a number of health and biotech companies worldwide including Agen Biomedical, Binax, Launch Diagnostics, AMRAD Biotech, AMRAD ICT, United Drug and his own start-up business in the UK, York Medical Technologies.

He has assisted in raising over $75m of venture investment and has held several chair and director roles with UniQuest’s biotech start-up companies including Coridon, Pepfactants, Q-Pharm and Vaxxas.

Dr Moss was part of the management team that worked with UniQuest’s Board in developing its strategy to simplify the business into two business offerings - IP Commercialisation and Expertise Commercialisation. The approach aims to optimise the delivery of commercialisation outcomes for UQ.

“Under Dean’s capable leadership, we are confident that UniQuest will continue to deliver to industry a quality suite of innovations and expertise capability from researchers at The University of Queensland,” Dr Hillyard said.